Document Detail

Drug updates and approvals: 2012 in review.
MedLine Citation:
PMID:  23295643     Owner:  NLM     Status:  MEDLINE    
Each year, the FDA approves many pharmaceuticals and products designed to treat or improve a patient's condition. The following is a sampling of some of the most important drugs approved in 2012 that specifically apply to nurse practitioner practice.
Jennifer M Belavic
Related Documents :
1812633 - Status epilepticus. clinical features, pathophysiology, and treatment.
23112813 - Characterizing the network of drugs and their affected metabolic subpathways.
20925643 - Nanotechnology for delivery of drugs and biomedical applications.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The Nurse practitioner     Volume:  38     ISSN:  1538-8662     ISO Abbreviation:  Nurse Pract     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-24     Completed Date:  2013-04-19     Revised Date:  2013-05-22    
Medline Journal Info:
Nlm Unique ID:  7603663     Medline TA:  Nurse Pract     Country:  United States    
Other Details:
Languages:  eng     Pagination:  24-42; quiz 42-3     Citation Subset:  IM; N    
University of Pittsburgh Medical Center-Presbyterian Hospital, Pittsburgh, PA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetanilides / therapeutic use
Adenine / analogs & derivatives,  therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Benzazepines / therapeutic use
Carbamates / therapeutic use
Deoxycytidine / analogs & derivatives,  therapeutic use
Drug Approval*
Drug Combinations
Fatty Alcohols / therapeutic use
Mifepristone / therapeutic use
Nicotinic Acids / therapeutic use
Nurse Practitioners
Organophosphonates / therapeutic use
Phosphatidylglycerols / therapeutic use
Prednisone / chemistry,  therapeutic use
Proteins / therapeutic use
Pyrimidines / therapeutic use
Quinolones / therapeutic use
Thiazoles / therapeutic use
United States
United States Food and Drug Administration*
Reg. No./Substance:
0/Acetanilides; 0/Antibodies, Monoclonal, Humanized; 0/Benzazepines; 0/Carbamates; 0/Drug Combinations; 0/Fatty Alcohols; 0/JTK 303; 0/Nicotinic Acids; 0/Organophosphonates; 0/Phosphatidylglycerols; 0/Proteins; 0/Pyrimidines; 0/Quinolones; 0/Thiazoles; 0/cobicistat; 0/emtricitabine; 0/lucinactant; 0/ranibizumab; 0/stribild; 107021-12-5/tenofovir; 118292-40-3/tazarotene; 53-03-2/Prednisone; 637E494O0Z/lorcaserin; 73-24-5/Adenine; 84371-65-3/Mifepristone; 951-77-9/Deoxycytidine; DR5S136IVO/avanafil; MVR3JL3B2V/mirabegron

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Adolescent concussions: When to return to play.
Next Document:  The European map of the geogenic radon potential.